3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Glioblastoma
45
Neuroblastoma
16
Glioma
16
Brain Neoplasms
14
Astrocytoma
10
Neoplasms
8
Rhabdomyosarcoma
7
Sarcoma, Ewing
6
Recurrence
5
Oligodendroglioma
5
Medulloblastoma
5
Sarcoma
4
Osteosarcoma
4
Melanoma
4
Small Cell Lung Carcinoma
3
Neuroendocrine Tumors
3
Neuroectodermal Tumors, Primitive
3
Lymphoma
3
Gliosarcoma
3
Diffuse Intrinsic Pontine Glioma
3
Wilms Tumor
2
Rhabdoid Tumor
2
Pyloric Stenosis, Hypertrophic
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Ganglioneuroblastoma
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Colorectal Neoplasms
2
Central Nervous System Neoplasms
2
Interventions
Magnetic Resonance Spectroscopy
51
Specimen Handling
42
enzalutamide
36
Androgen Antagonists
35
Radiosurgery
33
Radiotherapy
31
darolutamide
26
Prednisone
26
Abiraterone Acetate
25
Leuprolide
22
Docetaxel
22
apalutamide
21
abiraterone
19
Pluvicto
19
Standard of Care
18
Triptorelin Pamoate
17
Radiation
17
Biopsy
16
relugolix
15
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
15
Goserelin
14
Blood Specimen Collection
13
gallium 68 PSMA-11
12
X-Rays
11
Surveys and Questionnaires
11
pembrolizumab
10
luprolide acetate gel depot
10
Carboplatin
10
Methods
9
Interviews as Topic
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Prostatic Neoplasms
×
Temozolomide
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled